2 not yet recruiting, 1 recruiting. 3 Phase 2, 2 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 3 | Not yet recruiting 2, Recruiting 1 |
| Phase 1 | 2 | Not yet recruiting 2 |
Follow Advenchen Pharmaceuticals, LLC.: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study of Catequentinib Hydrochloride (AL3818) in Endometrial, LGSOC, STS or GBM Cancers AL58805, AL3818, Temozolomide (TMZ) - Endometrial Neoplasms, Ovarian Neoplasms | Phase 1 / Phase 2 | Not yet recruiting | Advenchen Pharmaceuticals, LLC. | 138 | 2026-09-01 | 2026-09-10 |
| A Study of AL58805 in Advanced, Metastatic GYN, STS or Breast Cancers AL58805, AL8326, Eribulin - Endometrial Neoplasms, Soft Tissue Sarcoma (STS) | Phase 1 / Phase 2 | Not yet recruiting | Advenchen Pharmaceuticals, LLC. | 138 | 2026-09-01 | 2026-09-10 |
| Phase 2 Study for the Patient, Who Has Diagnosed With Small Cell Lung Cancer (SCLC) or Non Small Cell Lung Cancer (NSCLC) or Renal Cell Carcinoma (RCC) and Finished the First Line Stand Treatment , Need More Treatment AL8326 40 mg, AL8326 60 mg, AL8326 80 mg--stopped - Small Cell Lung Cancer, Renal Cell Carcinoma (RCC) | Phase 2 | Recruiting | Advenchen Pharmaceuticals, LLC. | 80 | 2022-11-01 | 2026-05-08 |
Endometrial Neoplasms (2) · Sarcoma (2) · Breast Neoplasms (1) · Carcinoma, Non-Small-Cell Lung (1) · Carcinoma, Renal Cell (1) · Glioblastoma (1) · Ovarian Neoplasms (1) · Small Cell Lung Carcinoma (1)
Fulvestrant (1) · Lomustine (1) · Temozolomide (1) · anlotinib (1) · eribulin (1)
United States (3) · Spain (1)
Judy Chen (2) · Carlos K Matsuoka, MD (1) · Jeffrey A How, MD (1) · Saiama Waqar, MD (1)